Loading…
← CockpitCompetitor Analysis › SNDX Syndax Pharmaceuticals IncOpen in the cockpit ↗

Syndax Pharmaceuticals IncSNDXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops targeted oncology therapies including an approved menin inhibitor for genetically defined leukemias.

Momentum laggard 4
Mkt cap
$771M
US dollars, full cap
Free float
91%
of shares outstanding
$/day
$44.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-103.9 pp
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
104 days
2 Mar 2027
Close · USD$8.56
1D-7.0%
1W-10.7%
1M-35.4%
3M-56.7%
6M-57.5%
YTD-59.3%
1Y-50.2%
ATR %10.1%
Beta0.80
52w lowhigh66.5% off high

What Syndax Pharmaceuticals does

Develops targeted oncology therapies including an approved menin inhibitor for genetically defined leukemias.

Revuforj, approved in 2024 for relapsed acute leukemia with a certain gene change, is its own product, so sales rest on a small number of specialist cancer centres. Axatilimab, a graft-versus-host disease antibody, is developed and sold in partnership with Incyte.

Products and services

  • Revuforj (revumenib, menin inhibitor leukemia)
  • Axatilimab (chronic graft-versus-host disease, with Incyte)

Customers

  • Hematologist-oncologists/cancer centers

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Targeted oncology, menin inhibition

What could go right

  • Revuforj commercial launch uptake
  • Axatilimab royalty and commercial contribution

What could go wrong

  • Competitive menin inhibitor entrants
  • Commercial launch execution risk

Moat: narrow (IP / patents, regulatory licence). First approved menin inhibitor for a genetically defined leukemia subtype, with an Incyte GvHD partnership.

Headquarters: Waltham, Massachusetts, US · Founded: 2005 · Employees: 298

Named competitors

Syndax Pharmaceuticals at a glance

Size Syndax Pharmaceuticals (SNDX) is a United States Health Care company (Biotechnology) with a market value of $771M, the 2398th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.56 on 18 Nov 2026.

Performance Over six months the shares fell 57.5%, against -12.2% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 19 in its peer set.

Growth Revenue grew 159.7% over the last twelve months (peer median +5.2%); the operating margin is -61.7% (peer median -113.3%).

Valuation It trades at 3.2× enterprise value to sales against a peer median of 6.8× (3rd cheapest of 17).

Capital Return on invested capital runs 103.9 points below its cost of capital (6.6% WACC).

Credit Syndax Pharmaceuticals has 1 bond outstanding ($250M).

Short interest Short interest is 21.0% of the free float (30 Oct 2026).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

507510012521 May 202621 Aug 202618 Nov 2026Peer median 89SNDX 43
Six months, rebased to 100: Syndax Pharmaceuticals against the median of its 20 peers (local-currency closes).

Syndax Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$290M$172M$23.7M$0$0
Revenue growth—+628%———
Gross profit$267M$165M$22.8M-$12,000-$454,000
EBITDA-$179M-$273M-$340M-$230M-$151M
Net income-$209M-$285M-$319M-$209M-$149M
Free cash flow-$177M-$323M-$275M-$161M-$134M
Capital expenditure$96,000$187,000$0$0$0
Total debt$589M$345M$346M$1.64M$1.16M

Quarterly statements and history in the cockpit →

Syndax Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%-25%0%+25%+50%GLUE9887IVA688526AURA002038MGTXATTOVSTM45877729SNDX6-month return →1-month return →
Up and to the right = strong over both horizons. Syndax Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%0×5,000×10,000×GLUEIVA688526MGTXAPMDVSTMSNDXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Syndax Pharmaceuticals is the large dot.

Syndax Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (SNDX vs KURA vs INCY vs NOVN.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Syndax Pharmaceuticals SNDX$771M-57%+160%-62%3.2×n/a
Kura Oncology KURA$674M-29%-24%-394%2.6×n/a
Incyte INCY$24.0B+21%+25%12%3.4×14.2%
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%

How Syndax Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Syndax Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureSNDXPeer medianRank in peer set
1-month return-35.4%-6.2%lowest of 21
6-month return-57.5%-12.2%lowest of 19
Distance from 52-week high-66.5%-44.9%2nd lowest of 21
Revenue growth (TTM)+159.7%+5.2%4th highest of 15
Operating margin-61.7%-113.3%8th highest of 17
EV / Sales3.2×6.8×3rd cheapest of 17
ROIC minus cost of capital-103.9 pp-11.1 pplowest of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Syndax Pharmaceuticals SNDXUnited States$771M-57%+160%-62%3.2×n/an/a
Monte Rosa Therapeutics GLUEUnited States$775M-51%-61%-214%3.3×n/an/a
Nanjing Leads Biolabs 9887.HKHong Kong$764M-50%n/a-108%21.1×n/an/a
Inventiva IVA.PAFrance$763M-36%-100%-307,063%12,169.8×n/an/a
Wuhan Keqian Biology 688526.SSChina$780M-24%-22%20%4.4×7.8%+2.4%
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
MeiraGTx MGTXUnited States$813M-13%+1,366%44%1.9×n/an/a
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Oxford BioMedica OXB.LUnited Kingdom$841M-15%+16%-18%4.1×n/an/a
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Verastem VSTMUnited States$866M+66%+650%-194%8.2×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Peptidream 4587.TJapan$878M-3%+14%-18%6.6×n/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a

Syndax Pharmaceuticals bonds and credit

Syndax Pharmaceuticals has 1 bond outstanding with $250M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Syndax Pharmaceuticals's main competitors?
Named competitors: Kura Oncology (KURA), Incyte (INCY), Novartis (NOVN.SW). The cockpit's measured peer set (industry) also includes Monte Rosa Therapeutics (GLUE), Nanjing Leads Biolabs (9887.HK), Inventiva (IVA.PA), Wuhan Keqian Biology (688526.SS), Aura Biosciences (AURA), Beijing SL Pharmaceutical (002038.SZ).
Is Syndax Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 3.2× against a peer median of 6.8×, 3rd cheapest of 17 in its peer set.
How has Syndax Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -57.5% against -12.2% for the median peer; over one year -50.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.